We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
+16.44%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$13.3B
AUM Growth
+$1.82B
Cap. Flow
+$65.9M
Cap. Flow %
0.5%
Top 10 Hldgs %
32.36%
Holding
350
New
21
Increased
125
Reduced
153
Closed
21

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$72.8M
2
ABBV icon
AbbVie
ABBV
+$59.8M
3
PG icon
Procter & Gamble
PG
+$53.3M
4
VZ icon
Verizon
VZ
+$26.4M
5
AVGO icon
Broadcom
AVGO
+$19.9M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$79.9M
2
MCD icon
McDonald's
MCD
+$64.5M
3
EL icon
Estee Lauder
EL
+$57.4M
4
O icon
Realty Income
O
+$20.5M
5
AAPL icon
Apple
AAPL
+$18.6M

Sector Composition

Rank Sector Weight
1 Technology 21.17%
2 Healthcare 15.36%
3 Financials 13.42%
4 Consumer Staples 9.92%
5 Industrials 9.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MSFT icon
1
Microsoft
MSFT
$2.84T
$675M 5.08%
3,318,535
-36,040
-1% -$6.54M
HD icon
2
Home Depot
HD
$332B
$508M 3.82%
2,029,388
-642
-0% -$147K
NEE icon
3
NextEra Energy
NEE
$187B
$501M 3.77%
8,351,924
-85,572
-1% -$5.12M
PG icon
4
Procter & Gamble
PG
$343B
$410M 3.08%
3,428,092
+457,003
+15% +$53.3M
TXN icon
5
Texas Instruments
TXN
$255B
$396M 2.98%
3,121,138
+27,654
+0.9% +$3.22M
JPM icon
6
JPMorgan Chase
JPM
$939B
$373M 2.8%
3,962,604
-29,216
-0.7% -$2.77M
CSCO icon
7
Cisco
CSCO
$450B
$369M 2.78%
7,909,894
+45,008
+0.6% +$1.97M
PEP icon
8
PepsiCo
PEP
$186B
$360M 2.71%
2,721,859
+20,896
+0.8% +$2.75M
LMT icon
9
Lockheed Martin
LMT
$134B
$358M 2.69%
981,192
+15,107
+2% +$5.71M
CCI icon
10
Crown Castle
CCI
$32.7B
$351M 2.64%
2,096,592
+3,407
+0.2% +$549K
APD icon
11
Air Products & Chemicals
APD
$66.3B
$345M 2.6%
1,429,332
+16,364
+1% +$3.74M
JNJ icon
12
Johnson & Johnson
JNJ
$635B
$301M 2.26%
2,139,168
+39,366
+2% +$5.74M
HON icon
13
Honeywell
HON
$77.1B
$274M 2.06%
2,011,232
+12,613
+0.6% +$1.67M
TFC icon
14
Truist Financial
TFC
$63.2B
$273M 2.05%
7,269,576
+129,409
+2% +$4.66M
BLK icon
15
Blackrock
BLK
$164B
$267M 2.01%
491,285
+4,983
+1% +$2.52M
ABT icon
16
Abbott
ABT
$180B
$260M 1.96%
2,848,117
-6,462
-0.2% -$584K
ABBV icon
17
AbbVie
ABBV
$458B
$257M 1.94%
2,621,079
+678,689
+35% +$59.8M
MDLZ icon
18
Mondelez International
MDLZ
$77.7B
$253M 1.9%
4,941,954
+125,436
+3% +$6.44M
AVGO icon
19
Broadcom
AVGO
$1.82T
$236M 1.77%
7,465,620
+710,900
+11% +$19.9M
MRK icon
20
Merck
MRK
$324B
$235M 1.76%
3,179,433
+967,180
+44% +$72.8M
MRSH
21
Marsh
MRSH
$86.3B
$233M 1.75%
2,165,785
+23,037
+1% +$2.33M
MCD icon
22
McDonald's
MCD
$188B
$231M 1.74%
1,251,363
-351,802
-22% -$64.5M
ADP icon
23
Automatic Data Processing
ADP
$100B
$228M 1.72%
1,533,845
+5,087
+0.3% +$729K
PAYX icon
24
Paychex
PAYX
$40.4B
$216M 1.63%
2,855,108
+36,324
+1% +$2.52M
SBUX icon
25
Starbucks
SBUX
$118B
$214M 1.61%
2,913,675
-114,092
-4% -$8.57M

Similar funds

Bahl & Gaynor's Q2 2020 Portfolio in Review

As of Q2 2020, Bahl & Gaynor held 350 positions worth $13.3B, up 16% from $11.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bahl & Gaynor's Q2 2020 filing shows 21 new, 125 increased, 153 reduced and 21 closed positions. Its largest new stake was Otis Worldwide: 90,609 shares worth $5.15M. The largest sale was Pfizer, an estimated $79.9M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • Bahl & Gaynor's largest Q2 2020 buy was Otis Worldwide: 90,609 shares worth $5.15M.
  • Bahl & Gaynor added most to Merck in Q2 2020, an estimated $72.8M increase.
  • Bahl & Gaynor's biggest Q2 2020 reduction was Pfizer, cutting an estimated $79.9M.
  • Bahl & Gaynor fully exited Interparfums in Q2 2020, selling an estimated $4.84M.
  • Bahl & Gaynor's ten largest holdings make up 32% of its $13.3B portfolio in Q2 2020.
  • Bahl & Gaynor opened 21 new positions and closed 21 in Q2 2020.
  • Bahl & Gaynor's portfolio value rose 16% quarter-over-quarter to $13.3B.

Based on Bahl & Gaynor's 13F filing for Q2 2020, filed 13 Aug 2020.